Preprocedural Prognostic Factors in Acute Decompensated Aortic Stenosis.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 07 2022
Historique:
received: 25 01 2022
revised: 26 02 2022
accepted: 02 03 2022
pubmed: 9 5 2022
medline: 7 6 2022
entrez: 8 5 2022
Statut: ppublish

Résumé

Acute decompensated aortic stenosis (ADAS) is common and associated with poor outcomes. Myocardial remodeling and function, including a novel echo staging classification (0 to 4, representing increasing degrees of cardiac damage/dysfunction), impact outcomes in stable aortic stenosis. However, this has not been assessed in patients with ADAS. This study aims to evaluate the impact of the myocardium, echo staging classification, and clinical parameters on mortality in ADAS. ADAS was defined as an acute deterioration in symptoms (New York Heart Association 4, Canadian Cardiovascular Society 3/4, or syncope) that warranted admission to the hospital and urgent aortic valve replacement. Using a retrospective observational study design, 292 consecutive patients with ADAS who underwent transcatheter aortic valve implantation (TAVI) were identified and included in this study. Echocardiographic and clinical characteristics were evaluated using regression analysis. The outcome was all-cause mortality after TAVI. At 1 year after TAVI, advanced echo staging (>2) independently predicted mortality (hazards ratio: 1.85, 95% confidence interval: 1.01 to 3.39; p = 0.045). At a follow-up of 2.4 ± 1.4 years, myocardial, valvular, and clinical parameters did not predict mortality, except for frailty (hazards ratio: 2.31, 95% confidence interval: 1.38 to 3.85; p = 0.001). In patients with ADAS, short-term mortality after TAVI is influenced by more advanced cardiac damage/dysfunction based on the echo staging classification, whereas mid-term mortality is driven by frailty rather than echo staging classification.

Identifiants

pubmed: 35527043
pii: S0002-9149(22)00335-6
doi: 10.1016/j.amjcard.2022.03.037
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-100

Subventions

Organisme : British Heart Foundation
ID : FS/CRTF/21/24128
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.

Auteurs

Kush P Patel (KP)

Barts Heart Centre, St Bartholomew's Hospital, London; Institute of Cardiovascular Science, University College London, London.

Sveeta Badiani (S)

Barts Heart Centre, St Bartholomew's Hospital, London.

Ajithish Ganeshalingam (A)

Institute of Cardiovascular Science, University College London, London.

Mohit Vijayakumar (M)

Institute of Cardiovascular Science, University College London, London.

George Thornton (G)

Barts Heart Centre, St Bartholomew's Hospital, London; Institute of Cardiovascular Science, University College London, London.

Anthony Mathur (A)

Barts Heart Centre, St Bartholomew's Hospital, London; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London; Yale University School of Medicine, New Haven, Connecticut.

Simon Kennon (S)

Barts Heart Centre, St Bartholomew's Hospital, London.

Sanjeev Bhattacharyya (S)

Barts Heart Centre, St Bartholomew's Hospital, London.

Andreas Baumbach (A)

Barts Heart Centre, St Bartholomew's Hospital, London; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London; Yale University School of Medicine, New Haven, Connecticut.

James C Moon (JC)

Barts Heart Centre, St Bartholomew's Hospital, London; Institute of Cardiovascular Science, University College London, London.

Thomas A Treibel (TA)

Barts Heart Centre, St Bartholomew's Hospital, London; Institute of Cardiovascular Science, University College London, London.

Michael J Mullen (MJ)

Barts Heart Centre, St Bartholomew's Hospital, London; Institute of Cardiovascular Science, University College London, London.

Guy Lloyd (G)

Barts Heart Centre, St Bartholomew's Hospital, London; Institute of Cardiovascular Science, University College London, London; Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London. Electronic address: guy.lloyd1@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH